Camlin Fine Sciences to Issue ₹101.7 Crore Worth of Shares for Vinpai Acquisition

Mumbai, September 29, 2025 – Camlin Fine Sciences Limited (CFSL), a leading Indian player in shelf-life solutions and wellness ingredients, has approved the issuance of 41,06,181 equity shares at a price of ₹247.69 per share, aggregating to ₹101.7 crore, as part of its acquisition of French company Vinpai. The allotment will be made on a preferential basis, subject to shareholder approval through a postal ballot scheduled to conclude on October 29, 2025. This share issuance is a non-cash consideration towards acquiring a majority stake in Vinpai (Euronext Growth Paris: ALVIN), under a binding agreement signed in February 2025. The transaction also involves the issuance of convertible bonds that will convert into Vinpai shares, followed by a simplified cash tender offer (OPAS) for the remaining shares of Vinpai at €3.60 per share. The sellers of Vinpai, who collectively hold 78.68% of the share capital and 83.73% of voting rights, have completed Indian regulatory formalities including PAN registration, and are in the process of opening demat accounts to receive CFSL consideration shares. Upon allotment, the sellers will collectively hold 2.14% of CFSL’s equity. Timeline of the Transaction: Sept 29, 2025 – CFSL Board fixed subscription price and called for shareholder approval. Oct 29, 2025 – Postal ballot voting concludes. By Nov 12, 2025 – Allotment of CFSL shares to Vinpai sellers, subject to regulatory clearances. End-Nov 2025 – Filing of the draft OPAS with French regulator Autorité des marchés financiers (AMF). This move underscores CFSL’s global expansion strategy, strengthening its presence in Europe’s specialty ingredients market, while offering Vinpai access to growth capital and strategic synergies. ✅ Disclaimer: This article is for informational purposes only and should not be considered investment advice. 👉 Follow for more timely updates on corporate deals & financial developments.